STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #601 by analyst upside · 2026-06-27
JANX
Janux Therapeutics, Inc.
Healthcare · Market Cap $911M · P/E 0x
ANALYST PRICE TARGET
+148.9%
implied upside to consensus target
Current Price $14.94
Consensus Target $37.19
Bull Target $72.0
Bear Target $14.0
Analysts Covering 16
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
12
Hold
1
Sell
0
52-Week Low $12.12
52-Week High $35.34
YTD Return +9.5%
FUNDAMENTALS
Market Cap $911M
P/E Ratio (TTM) N/A
Forward P/E -5.5x
EPS (TTM) $-1.84
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $14M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $12.12
52-Week High $35.34
Current Price $14.94
Bear Target $14.0
Bull Target $72.0
● Now $14.94 ● Target $37.19
TRADING DATA
Avg Volume 1.1M
YTD Return +9.5%
Analyst Count 16
Consensus Buy
Upside to Target +148.9%
Last Updated 2026-06-27

ANALYST SUMMARY

Janux Therapeutics, Inc. (JANX) is currently trading at $14.94 with a Wall Street consensus price target of $37.19, implying potential upside of 148.9% over the next 12 months. 16 analysts currently cover JANX, with a consensus rating of Buy - 94% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $72.0, while the most cautious has a target of $14.0.

JANX operates in the Healthcare sector with a market capitalisation of $911M. The stock is up 9.5% year-to-date and is currently trading near the lower end of its 52-week range of $12.12 – $35.34.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for JANX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Piper Sandler — Reiterated
Overweight → Overweight 2026-05-08 14% win rate (7 calls)
Wedbush — Reiterated
Outperform → Outperform 2026-05-08 Building track record
Guggenheim — Reiterated
Buy → Buy 2026-05-08 62% win rate (8 calls)
Jones Trading — Reiterated
Buy → Buy 2026-04-28 57% win rate (14 calls)
Barclays ↓ Downgrade
Overweight → Underweight 2026-04-20 Building track record
UBS ↓ Downgrade
Buy → Neutral 2026-04-15 33% win rate (6 calls)
Cantor Fitzgerald — Reiterated
Overweight → Overweight 2026-02-27 40% win rate (10 calls)
Guggenheim — Reiterated
Buy → Buy 2026-02-27 62% win rate (8 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
44
out of 100
Coverage depth
22/30
Consensus clarity
0/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →